Core Viewpoint - ST Xiangxue announced the convening of its 31st meeting of the 9th board of directors on October 27, 2025, to review the full report for the third quarter of 2025 [1] Company Summary - For the first half of 2025, ST Xiangxue's revenue composition is as follows: Traditional Chinese medicine accounts for 64.87%, pharmaceutical manufacturing for 22.53%, other sectors for 20.22%, pharmaceutical distribution for 4.27%, and medical devices for 1.18% [1] - As of the report, ST Xiangxue has a market capitalization of 6.8 billion yuan [1]